Chemical Structure : Trastuzumab deruxtecan
CAS No.: 1826843-81-5
Catalog No.: PC-28465Not For Human Use, Lab Use Only.
Trastuzumab deruxtecan (T-DXd, DS-8201a) is a HER2-targeting antibody-drug conjugate with a topoisomerase I inhibitor exatecan derivative (DX-8951 derivative, DXd) at a drug-to-antibody ratio (DAR) of 7-8, shows potent antitumor activity HER2-positive cancers.
Bulk size, bulk discount!
E-mail: sales@probechem.com
Tech Support: tech@probechem.com
Trastuzumab deruxtecan (T-DXd, DS-8201a) is a HER2-targeting antibody-drug conjugate with a topoisomerase I inhibitor exatecan derivative (DX-8951 derivative, DXd) at a drug-to-antibody ratio (DAR) of 7-8, shows potent antitumor activity HER2-positive cancers.
Trastuzumab deruxtecan (T-DXd, DS-8201a) exhibits a HER2 expression-dependent cell growth-inhibitory activity and induced tumor regression with a single dosing at more than 1 mg/kg in a HER2-positive gastric cancer NCI-N87 model. Trastuzumab deruxtecan (T-DXd, DS-8201a) also shows an inhibitory activity to Akt phosphorylation.
Trastuzumab deruxtecan (T-DXd, DS-8201a) induces phosphorylation of Chk1 and Histone H2A.X, the markers of DNA damage. effective in a T-DM1-insensitive PDX model with high HER2 expression.
| M.Wt | 153000 (average) | |
| Formula | ||
| Appearance | Solid | |
| Storage |
|
|
| Solubility |
10 mM in DMSO |
|
| Chemical Name/SMILES |
|
|
1. Nagai Y, et al. Xenobiotica. 2019 Sep;49(9):1086-1096.
2. Iwata TN, et al. Mol Cancer Ther. 2018 Jul;17(7):1494-1503.
3. Ogitani Y, et al. Clin Cancer Res. 2016 Oct 15;22(20):5097-5108.

Copyright © 2022 probechem.com. All Rights Reserved. probechem Copyright